Prof David Thomas
I am an NHMRC Principal Research Fellow, Director of The Kinghorn Cancer Centre and Head of the Cancer Division of the Garvan Institute in NSW.
I undertook my medical training at the University of Melbourne (1982-88), followed by post-graduate training as a Fellow of the Royal Australasian College of Physicians in medical Oncology (awarded 1997). I undertook my doctoral studies at the University of Melbourne, and was awarded my PhD in 1997.
I undertook post-doctoral research at Harvard Medical School (1998-2000), before moving back to Melbourne to set up my own laboratory, initially at St Vincent’s Hospital (2001-3), then at Peter MacCallum Cancer Centre (2002-2014).
I was the founding Chair of the Australasian Sarcoma Study Group (2007-11), and am currently a board member and Deputy Chair. I was the Director of the adolescent and young adult (AYA) cancer program, onTrac@PeterMac (2005-10).
In the NewsNSW government funding a booster for the Cancer Moonshot - Jul 19, 2016
Landmark Lions project to provide genome sequencing to hundreds of Aussie kids with cancer - May 14, 2016
NHMRC funding success for Garvan researchers - Nov 09, 2015
Fashion heavyweights join forces to support Garvan for Fashion Targets Breast Cancer - Aug 14, 2015
Morning Tea Event Held for Garvan Supporters - Apr 23, 2015
Scientists solve mystery of ‘Frankenstein’ DNA - Nov 11, 2014
Garvan Institute scientists receive $10.7 million in NHMRC funding - Oct 22, 2014
Garvan Institute welcomes NSW funding of Sydney Genomics Collaborative - Jun 17, 2014
David Thomas appointed as new Director of The Kinghorn Cancer Centre - Dec 19, 2013
Awards and Honours
2012-2015 NHMRC Senior Research Fellow Level B
2011 - Victorian Cancer Agency, Clinician Researcher Fellowship
Western Australian Cancer Council visiting fellow
2009 - NHMRC Ten of the Best. Fellowship elected as one of the 10 best NHMRC investments for 2009
2008 - Sam Sciacca Visiting Fellow, Queensland Cancer Council
Associate Professor with title of Principal Research Fellow, University of Melbourne
2007-10 - Victorian Cancer Agency, Clinician Researcher Fellowship
2006-10 - Edna and Murray Dunn Award
2003-4 - Puzey fellowship, University of Melbourne
2003-7 - RD Wright NHMRC Career Development Award
2002 - Arnott Fellowship, Royal Australasian College of Physicians
2000 - John Taplin Fellow, Harvard Medical School
1998-2002 - Neil Hamilton Fairley National Health and Medical Research Council Fellowship
1997 - Fellowship of the Royal Australasian College of Physicians
1988 - Bachelor of Medicine and Surgery (University of Melbourne)
Burgess A, Chia KM, Haupt S, Thomas D, Haupt Y and Lim E. Clinical overview of MDM2/X-targeted therapies. Front Oncol 2016; 6:7.
McBride KA, Hallowell N, Tattersall MH, Kirk J, Ballinger ML, Thomas DM, Mitchell G and Young MA. Timing and context: important considerations in the return of genetic results to research participants. J Community Genet 2016; 7:11-20.
McBride KA, Schlub TE, Ballinger ML, Thomas DM and Tattersall MH. International survey of awareness of genetic risk in the clinical sarcoma community. Asia Pac J Clin Oncol 2016; doi: 10.1111/ajco.12457.
Ngiow SF, Loi S, Thomas D and Smyth MJ. Mouse Models of Tumor Immunotherapy. Adv Immunol 2016; 130:1-24.
Wong SQ, Fellowes A, Doig K, Ellul J, Bosma T, Irwin D, Vedururu R, Tan AY-C, Weiss J, Chan KS, Lucas M, Thomas DM, Dobrovic A, Parisot JP and Fox SB. Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients. Brit J Cancer 2015; 112:1411-1420.
Thomas DM, James PA and Ballinger ML. Clinical implications of genomics for cancer risk genetics. Lancet Oncol 2015; 16:e303-308.
Thomas DM and Ballinger ML. Etiologic, environmental and inherited risk factors in sarcomas. J Surg Oncol 2015; 111:490-495.
Thomas DM. The growing problem of benign connective tissue tumours. Lancet Oncol 2015; 16:879-880.
Mirabello L, Koster R, Moriarity BS, Spector LG, Meltzer PS, Gary J, Machiela MJ, Pankratz N, Panagiotou OA, Largaespada D, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, Caminada de Toledo SR, Petrilli AS, Patino-Garcia A, Sierrasesumaga L, Lecanda F, Andrulis IL, Wunder JS, Gokgoz N, Serra M, Hattinger C, Picci P, Scotlandi K, Flanagan AM, Tirabosco R, Fernanda Amary M, Halai D, Ballinger ML, Thomas DM, Davis S, Barkauskas DA, Marina N, Helman L, Otto GM, Becklin KL, Wolf NK, Weg MT, Tucker M, Wacholder S, Fraumeni JF, Jr., Caporaso NE, Boland JF, Hicks BD, Vogt A, Burdett L, Yeager M, Hoover RN, Chanock SJ and Savage SA. A genome-wide scan identifies variants in NFIB associated with metastasis in patients with osteosarcoma. Cancer Discov 2015; 5:920-931.
Chantrill LA, Nagrial AM, Watson C, Johns AL, Martyn-Smith M, Simpson S, Mead S, Jones MD, Samra JS, Gill AJ, Watson N, Chin VT, Humphris JL, Chou A, Brown B, Morey A, Pajic M, Grimmond SM, Chang DK, Thomas D, Sebastian L, Sjoquist K, Yip S, Pavlakis N, Asghari R, Harvey S, Grimison P, Simes J, Biankin AV, Australian Pancreatic Cancer Genome Initiative and the Individualized Molecular Pancreatic Cancer Therapy Trial Management Committee of the Australasian Gastrointestinal Trials Group. Precision medicine for advanced pancreas cancer: the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clin Cancer Res 2015; 21:2029-2037.
Ballinger ML, Mitchell G and Thomas DM. Surveillance recommendations for patients with germline TP53 mutations. Curr Opin Oncol 2015; 27:332-337.
Ashley D, Simes J, Thomas DM, Gore L, Carter R, Zalcberg J, Otmar R and Savulescu J. Accepting risk in the acceleration of drug development for rare cancers. Lancet Oncol 2015; 16:e190-194.
Wong SQ, Li J, Tan AY, Vedururu R, Pang JM, Do H, Ellul J, Doig K, Bell A, MacArthur GA, Fox SB, Thomas DM, Fellowes A, Parisot JP, Dobrovic A and Cohort C. Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med Genomics 2014; 7:23.
McBride KA, Ballinger ML, Killick E, Kirk J, Tattersall MH, Eeles RA, Thomas DM and Mitchell G. Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol 2014; 11:260-271.
Lewin J, Khamly K, Young R, Mitchell C, Hicks R, Toner G, Ngan S, Chander S, Powell G, Herschtal A, te Marvelde L, Desai J, Choong P, Stacker S, Achen M, Ferris N, Fox S, Slavin J, Binko J and Thomas DM. A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma. Br J Cancer 2014; 111:2254-2261.
Kansara M and Thomas DM. RB1-mediated cell-autonomous and host-dependent oncosuppressor mechanisms in radiation-induced osteosarcoma. Oncoimmunology 2014; 3:e27569.
Kansara M, Teng M, Smyth MJ and Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer 2014; 14:722-735.
Garsed DW, Marshall OJ, Corbin VDA, Hsu A, Di Stefano L, Schröder J, Li J, Feng Z-P, Kim BW, Kowarsky M, Lansdell B, Brookwell R, Myklebost O, Meza-Zepeda L, Holloway AJ, Pedeutour F, Choo KHA, Damore MA, Deans AJ, Papenfuss AT and Thomas DM. The architecture and evolution of cancer neochromosomes. Cancer Cell 2014; 26:653-667.
Kansara M, Leong HS, Lin DM, Popkiss S, Pang T, Garsed D, Walkley C, Cullinane C, Ellul J, Hicks R, Haynes N, Kuijjer M, Cleton-Jansen AM, Hinds PW, Smyth MJ, Thomas DM. Immune response to RB1-regulated senescence radiation-induced osteosarcoma formation. J Clin Invest 2013; 123:5351-5360.
Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, Dobrovic A, Slavin J, Choong PF, Simmons PJ, Dawid IB and Thomas DM. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 2009; 119:837-851.
Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B, Biology, Clinical Trials Subgroups of the USNCIPRGiA and Young Adult O. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer 2008; 8:288-298.
Thomas DM, Johnson SA, Sims NA, Trivett MK, Slavin JL, Rubin BP, Waring P, McArthur GA, Walkley CR, Holloway AJ, Diyagama D, Grim JE, Clurman BE, Bowtell DD, Lee JS, Gutierrez GM, Piscopo DM, Carty SA and Hinds PW. Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol 2004; 167:925-934.
Thomas DM, Carty SA, Piscopo DM, Lee JS, Wang WF, Forrester WC and Hinds PW. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell 2001; 8:303-316.